Omalizumab

Red

Brand Name(s):Xolair

Indication:Asthma -Severe persistent allergic, in patients with convincing IgE mediated asthma. Chronic spontaneous urticaria

Rationale:1,2,3,8

Considered:Sep-06

Review Date:Jun-20

Comments:
Omalizumab: potential risk of arterial thrombotic events
NICE TA 339
Omalizumab for previously treated chronic spontaneous urticaria
Full guidance can be found at:http://www.nice.org.uk/guidance/ta339/resources/guidance-omalizumab-for-previously-treated-chronic-spontaneous-urticaria-pdf
June 2015